MT2020-27: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of a relapse or refractory large B cell lymphoma, for which treatment with Kymriah is planned - received two or more lines of systemic therapy - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - participants of child bearing age must use birth control for 30 days following completion of treatment - additional inclusion criteria (study staff will review)

Exclusion Criteria:

- women who are pregnant or breast feeding - CNS involvement by malignancy - eye disease or complaints visual acuity impairment, color or shape distortion, or blurred vision

•potential participants are required to have an eye exam as part of screening - additional exclusion criteria (study staff will review)

Conditions & Interventions

Interventions:
Drug: E7777
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Diffuse Large B Cell Lymphoma, DLBCL, High-grade B-cell Lymphoma

More Information

Description: This purpose of this study is to identify a safe dose level for the study drug, E7777, when given with standard tisagenlecleucel therapy (also known by its brand name, Kymriah, is an immunotherapy that is made from the participants own blood cells) in participants with Diffuse Large B-Cell Lymphoma (DLBCL). Up to three dose levels of E7777 will be tested.
Study Contact: Eric Homan - homa0030@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: Phase 1/Phase 2
IRB Number: STUDY00011895